The drug-resistant fungus Candida auris has now been detected in at least 27 US states in 2026, with 3,437 clinical cases reported to the Centers for Disease Control and Prevention as of early August. If you are a healthy person going about your day, this is not an infection you are likely to catch.
Candida auris is a hospital pathogen. It is almost entirely a threat to people who are already very ill, in intensive care, on ventilators or catheters, or living in long-term care facilities. The CDC classifies it as an urgent antimicrobial resistance threat precisely because it spreads inside these settings, not in homes or public spaces.
Who is actually vulnerable
The people most at risk are hospitalized patients with serious underlying conditions, those with weakened immune systems, and residents of nursing homes and long-term acute care. Invasive medical devices such as central lines and breathing tubes give the fungus a path into the bloodstream, where it can cause severe infections and sepsis.
Symptoms are not specific to the fungus itself. Fever and chills that do not improve after antibiotic treatment are one signal doctors look for in patients already being cared for in these settings. Diagnosis requires laboratory testing.
Candida auris was first identified in Japan in 2009 and first reported in the United States in 2016. Case counts have climbed sharply since.
Why hospitals are on high alert
The alarm is about resistance. A CDC study of 8,033 clinical isolates collected during 2022 and 2023, published in the journal Emerging Infectious Diseases in February 2026, found that 95 percent were resistant to fluconazole, a common first-line antifungal drug. Fifteen percent were resistant to amphotericin B.
The better news in that data set is that only about 1 percent were resistant to echinocandins, the class of antifungals now used as first-line therapy for serious Candida auris infections. Fewer than 1 percent of samples were resistant to all three drug classes. Echinocandin resistance has stayed roughly stable, which is why the drugs remain the mainstay of treatment.
The fungus is also stubborn on surfaces. It can persist on medical equipment, bed rails and hospital furniture and tolerates some standard cleaning products, which is why infection control teams use specific disinfectants and screen patients transferring in from other facilities.
Also read: What omega-3 may do to your brain - and which people benefit most from taking it
What healthy people can take from this
For someone not in a hospital or nursing home, the day-to-day risk from Candida auris is very low. It is not a foodborne illness, it does not spread through casual contact in the community, and healthy immune systems handle Candida species that live harmlessly on skin.
The practical point for the general public is different. If you have a family member in intensive care, on a ventilator or in long-term care, healthcare-associated infections are a real concern. Ask staff about hand hygiene, question whether central lines and urinary catheters are still needed, and follow visitor protocols the facility sets.
Anyone caring for a hospitalized relative who develops a new fever or signs of infection that are not responding to treatment should raise it with the medical team.
Also read: A 'normal' kidney test can still hide a threefold dialysis risk, study finds
Also read: Three-quarters of common sweeteners may be quietly changing your gut bacteria